TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: Development of Mobile Technologies for the Prevention of Cervical Cancer in Santiago, Chile: A Randomized Controlled Trial.
Brief Summary: The purpose of this study is to evaluate the implementation and effectiveness of text messages as a means for improving adherence to cervical cancer screening.


Options:
A: Proportion of women who received a Pap smear within 6 months from the date when the study randomization began. (6 months after randomization of study)
B: Viral load (6 months post-randomization)
C: Uptake of the timed appointment provided by the screening service (Usually within a month (Individual timed appointment is provided by the screening service))
D: Proportion of fully immunized children (When the participants reach 2 years of age)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Development of Mobile Technologies for the Prevention of Cervical Cancer in Santiago, Chile: A Randomized Controlled Trial.
Brief Summary: The purpose of this study is to evaluate the implementation and effectiveness of text messages as a means for improving adherence to cervical cancer screening.


Options:
A: MEMS Adherence (12 months follow up)
B: Mammogram receipt (1 week)
C: Proportion of women who received a Pap smear within 6 months from the date when the study randomization began. (6 months after randomization of study)
D: Proportion of men failing to return for a post-operative clinic visit at 7 days. (7 days); Proportion of men who report resumption of sexual activity before 42 days post-circumcision. (42 days)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Development of Mobile Technologies for the Prevention of Cervical Cancer in Santiago, Chile: A Randomized Controlled Trial.
Brief Summary: The purpose of this study is to evaluate the implementation and effectiveness of text messages as a means for improving adherence to cervical cancer screening.


Options:
A: Proportion of fully immunized children (When the participants reach 2 years of age)
B: Proportion of women who received a Pap smear within 6 months from the date when the study randomization began. (6 months after randomization of study)
C: Number of Participants Who Report Starting Any Modern Method of Contraception Since the Start of the Study (4-months post-encouragement)
D: Smoking status by collecting an expired carbon monoxide breath sample (3-Month Follow-Up)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Musik Als Nicht-pharmakologische Intervention Zur Behandlung Von Schlafstörungen Bei Patienten Mit Depressiven Erkrankungen
Brief Summary: The purpose of this study is to determine whether music hearing in the evening before going to sleep can improve sleep quality, depressive symptoms and quality of life in patients with affective disorders.


Options:
A: Sleep Quality - subjective (Change of sleep quality from baseline at 4 weeks)
B: Score on Pittsburgh Sleep Quality Index (PSQI) (3 months)
C: Study Measures Completion (Baseline); Study Measures Completion (4 weeks); Acceptability of the study components (4 weeks)
D: objective sleep Quality (up to four weeks)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Randomised Controlled Trial of the Clinical and Cost Effectiveness of NICE Recommended Problem Solving Cognitive Behaviour Therapy (PS CBT) Delivered Remotely Versus Treatment as Usual in Adolescents and Young Adults With Depression Who Repeatedly Self-harm
Brief Summary: A randomized controlled trial to test the whether remote delivery of cognitive based therapy (CBT) is clinically and cost effective when compared to treatment as usual in adolescents and young adults with depression who self-harm.


Options:
A: Outcome Questionnaire -45.2 (Lambert et al., 2004) (3 months)
B: Beck Depression Inventory (V2) (Baseline to 6 months)
C: Beck scale for suicidal ideation (six months)
D: Deliberate Self-harm Inventory (DSHI; Gratz, 2001) and Lifetime Suicide Attempt Self-Injury interview (LSASI; formerly Lifetime Parasuicide Count, Linehan MM, Comtois KA, unpublished manuscript, 1996) (baseline; 10 weeks; 20 weeks; 3 month follow up)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Randomised Controlled Trial of the Clinical and Cost Effectiveness of NICE Recommended Problem Solving Cognitive Behaviour Therapy (PS CBT) Delivered Remotely Versus Treatment as Usual in Adolescents and Young Adults With Depression Who Repeatedly Self-harm
Brief Summary: A randomized controlled trial to test the whether remote delivery of cognitive based therapy (CBT) is clinically and cost effective when compared to treatment as usual in adolescents and young adults with depression who self-harm.


Options:
A: Scale for Suicide Ideation Index (SSI) (Over 8 weeks of treatment); Columbia Suicide Severity Rating Scale (C-SSRS): the Suicidal Ideation Scale (8 weeks of treatment)
B: Suicide re-attempt rate reduction using the Columbia Suicide Severity Rating Scale (C-SSRS) (At 2 years after the intervention)
C: Beck Depression Inventory (V2) (Baseline to 6 months)
D: Repeat Suicide Attempts (1, 2, and 3 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Randomised Controlled Trial of the Clinical and Cost Effectiveness of NICE Recommended Problem Solving Cognitive Behaviour Therapy (PS CBT) Delivered Remotely Versus Treatment as Usual in Adolescents and Young Adults With Depression Who Repeatedly Self-harm
Brief Summary: A randomized controlled trial to test the whether remote delivery of cognitive based therapy (CBT) is clinically and cost effective when compared to treatment as usual in adolescents and young adults with depression who self-harm.


Options:
A: Beck Depression Inventory (V2) (Baseline to 6 months)
B: Change in suicidal ideation severity as measured by the Suicidal Ideation Questionnaire - Jr (Screening, 6 weeks, 24 weeks)
C: Change in BPD (Borderline Personality Disorder) behaviors (8-weeks)
D: The number of contacts with mental health services appropriate to the patient's needs. (3 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Early Use of Transjugular Intrahepatic Portosystemic Shunt (TIPSS) in Patients With Cirrhosis and Variceal Bleeding
Brief Summary: Gastro-oesophageal varices (swollen veins in the gullet and stomach) are present in 50% of patients with liver cirrhosis and are its most serious complication as their rupture results in potentially life threatening bleeding. Bleeding from these veins occurs in up to one third of patients with varices. This is associated with 20% mortality at 6 weeks.

In the event of bleeding from these veins the current UK guidelines recommend certain drugs followed by early endoscopic treatment with variceal band ligation (rubber bands placed over the veins to stop them bleeding). The use of a shunt inside the liver ("TIPSS" transjugular intrahepatic portosystemic shunt) is largely reserved for cases of uncontrolled bleeding from these swollen veins. A recent randomised multicenter study carried out by Garcia Pagan and colleagues reported improved survival with early TIPSS in patients with bleeding from these swollen veins in advanced liver disease. From these guideline international guidelines now recommend consideration of early TIPSS for all high-risk patients presenting with variceal bleeding. This practice clearly has significant cost implications. To validate the findings a further randomised control trial is needed.

This is a multi-center parallel-group randomized controlled trial. Both hospitals taking part in the trial will have a TIPSS service. Patients who consent to enter the trial will be randomized to either: (1) Endoscopic treatment (standard care) or (2) early TIPSS.

Potential participants will be all patients with a diagnosis of liver cirrhosis presenting with an acute variceal bleed to a participating hospital who do not fulfill an exclusion criteria. All causes of cirrhosis will be included.

Participants will be reviewed during their regular hepatology clinic appointments at their respective hospitals on 3 occasions over a one-year period.


Options:
A: Survival (One Year)
B: Survival (10 years)
C: Survival (10 years)
D: Survival (10 years)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Lowering Blood Pressure in Primary Care in Vienna
Brief Summary: The aim of this prospective, randomised, open-label, multicentre clinical trial is to enhance blood pressure control in primary care by introducing a standardised and simplified titration regime with single pill combinations (SPC), comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide.


Options:
A: Cognitive Assessment: Trail Making Test Part B (Baseline-12 months); Cognitive Assessment: Hopkins Verbal Learning- Immediate Recall (Baseline-12 months); Cognitive Assessment: Forward Digit Span Test (Baseline-12 months)
B: Number of Participants With First Occurrence of a Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), Stroke, Heart Failure (HF), or CVD Death (6 years)
C: Achievement of the target office blood pressure (< 140/90 mmHg) (6 months); Achievement of the target systolic office blood pressure (< 140 mmHg) (6 months); Achievement of the target diastolic office blood pressure (< 90 mmHg) (6 months)
D: The primary study outcomes are composite of non-fatal stroke, non-fatal myocardial infarction and cardiovascular death. (3-4 years)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: A Single Blind, Randomised, Controlled Trial to Evaluate the Effectiveness of Transcutaneous Posterior Tibial Nerve Stimulation (TPTNS) in Overactive Bladder (OAB) Symptoms in Women Responders to Posterior Tibial Nerve Stimulation (PTNS)
Brief Summary: This study will help to determine the effectiveness of a self-supervised, home-based Transcutaneous Posterior Tibial Nerve Stimulation treatment protocol in maintaining Overactive Bladder (OAB) symptoms improvement in women responders to Posterior Tibial Nerve Stimulation (PTNS)


Options:
A: Proportion of Patients Reporting "Moderately" or "Markedly" Improved on the Global Response Assessment (GRA) at 36 Months as Compared to Baseline (36 months total)
B: The Global Response Assessment (GRA) for Overall Bladder Symptoms to Compare the Proportion of Subjects Reporting "Moderately" or "Markedly Improved" Responses on the GRA After 12 Interventions of Randomized Therapy, in an Intent to Treat Analysis. (13 weeks)
C: Frequency of Voids at 12 Weeks (Baseline to 12 weeks)
D: Changes in 24-hour micturition frequency (Bladder diaries completed at recruitment and 6 weeks, 12 weeks and 6 months.)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Making Effective HPV Vaccine Recommendations
Brief Summary: Coverage of HPV vaccination among US teens is low, far below Healthy People 2020 goals. A central reason for low coverage is infrequent and inadequate healthcare provider recommendation of HPV vaccine. The proposed intervention aims to train clinicians to provide effective recommendations for the vaccine using participatory or efficient communication strategies.

This study will evaluate the effectiveness of two communication trainings to increase HPV vaccination coverage among adolescent patients. We will compare HPV vaccination for pediatric and family medicine clinics receiving a participatory communication training, efficient communication training, or no training. Ten clinics will be randomly assigned to each study arm for a total of 30 clinics. The primary outcome of this study is to compare the change in clinics' levels of HPV vaccination initiation coverage among 11-12 year old adolescent patients from baseline to 6 month follow-up. Secondarily, we will compare the change in HPV vaccination initiation coverage in 13-17 year old adolescents.


Options:
A: Parental Vaccine Hesitancy Measure (Change from Baseline in Parental Hesitancy at 6 months)
B: Primary Outcome (3/1/2011-2/29/2012)
C: 6 month % change in HPV vaccination (≥ 1 dose), control vs. each intervention arm (efficient or participatory), 11-12 year olds (Baseline, month 6)
D: Change from baseline in number of child maltreatment protective factors available to caregiver at 6 months, as measured on the Quality Improvement Center on Early Childhood (QIC) "Caregivers Assessment of Protective Factors" (t1 (Baseline): at recruitment, prior to intervention; and t2: 6 months later); Change from baseline in number and amount of income supports available to and accessed by caregiver at 6 months, as measured on the Quality Improvement Center on Early Childhood (QIC) "Self-Report Family Inventory" + supplementary questions on $ value (t1 (Baseline): at recruitment, prior to intervention; and t2: 6 months later); Change from baseline in social capital available to caregiver at 6 months, as measured on the Quality Improvement Center on Early Childhood (QIC) "Social Network Grid" (t1 (Baseline): at recruitment, prior to intervention; and t2: 6 months later); Change from baseline in parental stress at 6 months, as measured by the "Parenting Stress Index (PSI) - long form" (t1 (Baseline): at recruitment, prior to intervention; and t2: 6 months later); Change from baseline in parenting and child-rearing attitudes of child's caregiver at 6 months, as measured on the "Adult-Adolescent Parenting Inventory(AAPI-2)" (t1 (Baseline): at recruitment, prior to intervention; and t2: 6 months later)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: A Pilot Prospective, Randomized Controlled Trial Assessing the Clinical Impact of Integrated Pharmacogenetic Testing on Selected OASIS Metrics, Re-hospitalizations and Emergency Department Visits
Brief Summary: Patients meeting eligibility criteria will be randomized into two groups, one receiving pharmacogenetic testing and the other not receiving pharmacogenetic testing. In this open-label trial, a pharmacist will make medication therapy recommendations using YouScript® Personalized Prescribing System for patients who receive genetic testing and standard drug information resources per usual for patients who do not undergo pharmacogenetic testing.


Options:
A: Number of Re-hospitalizations at 30 and 60 Days (30 days, 60 days post discharge); The Primary Outcomes Included the Number of Emergency Department Visits at 30 and 60 Days. (30 days, 60 days post discharge)
B: The primary outcome of this study will be focused on changes in doctor behavior and the comparison of the number of diagnostic tests ordered (chest x-rays) and antibiotics prescribed per patient encountered per diagnosis. (Comparisons between case and control ordering will be measured after a year of using the EMR tool)
C: Mortality (at 90 days)
D: referral to a nephrologist (12 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: AMOS2 (Adolescent Morbid Obesity Surgery)
Brief Summary: Severe childhood obesity is associated with both immediate and chronic health problems and a severe impact on psychosocial development. Medical and behavioural interventions rarely result in the significant, durable weight loss necessary to improve health outcomes.

This is a randomised clinical trial where 50 adolescents, 13-16 years of age, will be randomised to either early bariatric surgery (Roux-en-Y gastric bypass) or intense conservative treatment and possibly surgery after two years of non-surgical treatment or as they have become 18 years.


Options:
A: Body Mass Index (kg/m2) (2 years after treatment initiation)
B: Weight (6 months); Weight (12 months); Weight (24 months); Weight (36 months)
C: growth disorders (18 years); obesity (18 years)
D: Primary Safety Endpoint (12 months); Primary Efficacy Endpoint (12 months); Co-Primary Efficacy Endpoint (12 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: RCT on Care Manager Organization for Management of Mild-moderate Depression in the Primary Care Setting, Sweden
Brief Summary: The aim of the project is to explore if a complementary addition of a care manager for depression treatment in the primary care setting has positive effects concerning reduction of the patients' depressive symptoms as well as improvement of daily function and quality of life in a short- and long-term perspective compared with the traditional Swedish primary care organization. The aim is also to evaluate the care manager function in a health economic perspective.

The specific aims are to develop and evaluate an evidence-based care manager program for patients with mild to moderate depression and to compare the evidence-based care manager program to treatment as usual (TAU) in terms of their short- and long-term effects on symptom remission, treatment adherence, care satisfaction, and self-efficacy as well as to perform a cost - effectiveness analysis of the care manager program, i.e. to evaluate the effects of the program on patients' health in relation to the running costs of the program.


Options:
A: Change of level of depression (Self-reported level of depressive symptoms measured by Beck Depression Inventory II) (0- 6 months)
B: Return to work (at 6, 12, 24 and 60 months)
C: Psychological symptoms (Change from baseline to after treatment (6-9 weeks), 3 and 12 months)
D: Mean Change From the End of Phase A (Week 8 Visit) to Phase B (Week 14 Visit) in the Montgomery-Asberg Depression Rating Scale for the Efficacy Sample Set (Baseline and Week 14); Mean Change in MADRS Total Score From Baseline End of Week 8 to Week 14 for the Efficacy Sample Per Final Protocol (Baseline and Week 14)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Effect of Fee on Attendance in Cervical Cancer Screening-results From ScreenFee a Swedish Population Based Randomised Trial
Brief Summary: Several reasons can explain non-attendance in cervical cancer screening. In low resource settings the attendance is even lower. The effect of fee as contributing reason of non attendance has not been studied before why the investigators decided to study this in a low resource setting as a randomised trial.


Options:
A: The proportion of control and intervention subjects who are current on EACH individual indicated preventive service (Annual for three years); The proportion of control and intervention subjects who are current on ALL indicated preventive services (Annual for three years); The mean score for intervention and control subjects for quality of clinician communication (CAPHS-CGS questions 14-20); and frequency with which patients report sharing medical decisions (CAHPS questions SD 1-3) (Annual for three years)
B: Women who participate by returning a HPV self-sampling kit or having a practitioner-collected sample in the intervention groups compared to the proportion of women who have a practitioner-collected sample in the control group at 90 days after mail out. (90 days)
C: Difference in attendance (6 months)
D: Number of Participants Completing a Self-sampling Test (2 to 6 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Saline Hypertonic in Preschoolers
Brief Summary: The purpose of this study is to assess whether inhalation of 7% hypertonic saline (HS) twice daily for 48 weeks improves the lung clearance index by multiple breath nitrogen washout in comparison with inhalation of 0.9% isotonic saline (IS) in preschool children (ages 3 to 5) with cystic fibrosis.


Options:
A: The change in LCI from baseline to end of treatment in rhDnase treated patients versus patients receiving placebo (The duration of the patient's involvement in the study (approximately 3 months))
B: The rate of protocol-defined pulmonary exacerbations requiring treatment with oral, inhaled or intravenous antibiotics between subjects randomized to HS and IS (during the 48 week treatment period)
C: Change in Lung Clearance Index (LCI) (48 weeks)
D: Change in Mucociliary Clearance Rate (Baseline versus after completion of 4 week treatment period)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: The Clinical Results After Frozen-thawed Healthy Blastocyst Transfer in Natural Cycle Versus Cycle With Endometrial Preparation
Brief Summary: This study evaluates the difference in pregnancy rate transferring a healthy blastocyst in natural or artificial cycle.


Options:
A: number of retrieved oocytes (at the ovarian puncture, 36 hours post HCG administration)
B: Implantation rate (20 days after the embryo transfer)
C: clinical pregnancy rate confirmed by ultrasound evidence of fetal heart activity (12 weeks after embryo transfer)
D: Percentage of Participants With an Ongoing Pregnancy (Ongoing Pregnancy Rate) (Assessed at least 10 weeks after embryo transfer (up to 1 year)); Mean Number of Oocytes Retrieved (Up to 36 hours after administration of hCG (up to 1 year))

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Evaluation of a Tailored Virtual Intervention as an Instrument of Prevention and Support to Improve the Health of PLHIV and Reduce Comorbidity Associated With HIV (MP-02-2015-5853)
Brief Summary: The purpose of this study is to evaluate the efficacy of a web-based tailored intervention to support persons living with HIV (PLHIV) manage the demands inherent to their health condition, particularly as regards to the adoption of health behaviours such as being physically active, following a healthy diet and quitting smoking.

This randomized controlled trial is currently conducted entirely online at www.lhivehealthy.ca


Options:
A: 7-day point prevalence abstinence (Measured at Months 3, 6, and 12)
B: Abstinence for 7 consecutive days and 24 hours at 1, 3, and 6 months
C: N/A
D: Change in tobacco smoking (6 months); Change in level of physical activity (6 months); Change in diet quality (6 months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis
Brief Summary: The primary objective of the study is to assess the clinical efficacy of repeat subcutaneous (SC) doses of dupilumab, compared with placebo, to relieve symptoms in adult participants with active, moderate to severe Eosinophilic Esophagitis (EoE).

The secondary objectives of the study are:

* To assess the safety, tolerability, and immunogenicity of SC doses of dupilumab in adult participants with active, moderate to severe EoE
* To assess the effect of dupilumab on esophageal eosinophilic infiltration
* To evaluate the pharmacokinetics (PK) of dupilumab in adult participants with EoE


Options:
A: Safety and tolerability will be determined by evaluation of adverse events, vital sign monitoring, physical examination, electrocardiograms, lung function and laboratory assessments. (12 weeks after last dose)
B: Absolute Change From Baseline in Straumann Dysphagia Instrument (SDI) Patient Reported Outcome (PRO) Total Score at Week 10 (Baseline, Week 10)
C: Number of Participants With Histologic Response at the Final Treatment Period Evaluation (Week 16) (Week 16); Number of Participants With Dysphagia Symptom Response at the Final Treatment Period Evaluation (Week 16) (Week 16)
D: Change in Eosinophil Numbers Per High Power Field Proximally and Distally Between Baseline and Post-treatment and Between Both Groups (16 weeks)

Answer: B